BMC Racing Team have announced that they have terminated the contract of Samuel Sánchez following the analysis of his B sample from an out-of-competition test which confirmed the presence of growth hormone releasing peptide GHRP-2.

Sánchez was notified of the Adverse Analytical Finding (AAF) of GHRP-2 in a sample collected in an out-of-competition control on 9 August 2017 two days prior to the start of the Vuelta a España and he was subsequently suspended by BMC Racing.

The 39 year-old won the 2008 Olympic Road Race in addition to stages at both the Tour de France and Vuelta a España during his eighteen-year professional career. He also won the Vuelta a Burgos (2010) Tour of the Basque Country (2012) and Züri-Metzgete (2006).

GHRP-2 was also the substance which the Bardiani CSF riders’ Nicola Ruffoni and Stefano Pirazzi tested positive for on the eve of the Giro d’Italia.

The statement the team released is as follows:

“BMC Racing Team was previously informed by the Union Cycliste Internationale (UCI) of a potential anti-doping violation for the presence of GHRP-2 and its metabolite, in an out-of-race anti-doping control for Samuel Sánchez Gonzalez.

“In accordance with BMC Racing Team’s zero tolerance policy with respect to doping violations and UCI regulations, Sánchez was immediately suspended from BMC Racing Team. At the request of Sánchez, his B sample was analysed at the WADA accredited laboratory in Lausanne, Switzerland. The analysis of Sánchez’ B sample confirmed the presence of GHRP-2 and its metabolite, as found in his A sample. At that time, Sánchez’ contract with the team was terminated with immediate effect.”

5 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here